These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 37678927)
1. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with Murthy V; Gafita A; Thin P; Nguyen K; Grogan T; Shen J; Drakaki A; Rettig M; Czernin J; Calais J J Nucl Med; 2023 Nov; 64(11):1737-1743. PubMed ID: 37678927 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Performance of RECIP 1.0 Based on [ Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363 [TBL] [Abstract][Full Text] [Related]
3. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. Gafita A; Rauscher I; Weber M; Hadaschik B; Wang H; Armstrong WR; Tauber R; Grogan TR; Czernin J; Rettig MB; Herrmann K; Calais J; Weber WA; Benz MR; Fendler WP; Eiber M J Nucl Med; 2022 Nov; 63(11):1651-1658. PubMed ID: 35422442 [TBL] [Abstract][Full Text] [Related]
4. RECIP 1.0 Predicts Progression-Free Survival After [ Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Solnes LB; Calais J; Rettig MB; Weber M; Farolfi A; Benz MR; Eiber M J Nucl Med; 2024 Jun; 65(6):917-922. PubMed ID: 38637143 [TBL] [Abstract][Full Text] [Related]
5. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Gafita A; Rauscher I; Fendler WP; Murthy V; Hui W; Armstrong WR; Herrmann K; Weber WA; Calais J; Eiber M; Weber M; Benz MR Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4271-4281. PubMed ID: 35767071 [TBL] [Abstract][Full Text] [Related]
6. Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy. Widjaja L; Werner RA; Krischke E; Christiansen H; Bengel FM; Bogdanova N; Derlin T Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):602-612. PubMed ID: 36136101 [TBL] [Abstract][Full Text] [Related]
7. The Prognostic Value of Posttreatment Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906 [No Abstract] [Full Text] [Related]
8. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [ Song H; Leonio MI; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Shah J; Bergstrom CP; Fan AC; Shah S; Khaki AR; Srinivas S; Iagaru A Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2784-2793. PubMed ID: 38635050 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Tumor Volume Assessment on PSMA PET After Kind F; Eder AC; Jilg CA; Hartrampf PE; Meyer PT; Ruf J; Michalski K J Nucl Med; 2023 Apr; 64(4):605-610. PubMed ID: 36302658 [TBL] [Abstract][Full Text] [Related]
10. Response assessment using Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186 [TBL] [Abstract][Full Text] [Related]
11. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer. Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963 [TBL] [Abstract][Full Text] [Related]
12. A Single-Arm, Low-Dose, Prospective Study of Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486 [TBL] [Abstract][Full Text] [Related]
13. The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy. Karimzadeh A; Heck M; Tauber R; Solaris E; Nekolla S; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I J Nucl Med; 2023 Aug; 64(8):1252-1258. PubMed ID: 37290796 [TBL] [Abstract][Full Text] [Related]
14. Early molecular imaging response assessment based on determination of total viable tumor burden in [ Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725 [TBL] [Abstract][Full Text] [Related]
15. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019 [TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of [ Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824 [No Abstract] [Full Text] [Related]